Canbex Therapeutics Ltd

Canbex is a spinout of University College London (UCL) that was established to develop its proprietary VSN compound series. In addition to its pioneering scientific founders and clinical advisors, Canbex has assembled a skilled and focused management team. Development activities are carried out through leading CROs and CMOs. The company’s capital efficiency and lean management strategy ensure that funds are deployed directly to compound development. Investors include the Wellcome Trust, MS Ventures, Fast Forward LLC, UCL Business Plc and Esperante.

Year founded

2004

canbex.co.uk